Galectin Sciences LLC (Details) - Galectin Sciences, LLC [Member] - USD ($) |
1 Months Ended | 3 Months Ended | 12 Months Ended | 108 Months Ended | 144 Months Ended | ||
|---|---|---|---|---|---|---|---|
Jan. 31, 2014 |
Dec. 31, 2014 |
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2014 |
Dec. 31, 2023 |
Dec. 31, 2025 |
|
| Galectin Sciences LLC [Abstract] | |||||||
| Initial cash investment | $ 400,000 | ||||||
| Ownership percentage | 85.50% | 85.50% | |||||
| Amount expanded in cash | $ 400,000 | ||||||
| Contribution for expenses | $ 73,000 | $ 57,000 | $ 350,000 | $ 3,326,000 | |||
| Loss from equity method investment | $ 400,000 | ||||||
| Non-cash charge for in-process research and development | $ 200,000 | ||||||
| SBH [Member] | |||||||
| Galectin Sciences LLC [Abstract] | |||||||
| Ownership percentage | 50.00% | ||||||
| Contribution for expenses | $ 711,000 | ||||||
| SBH [Member] | IPR&D [Member] | |||||||
| Galectin Sciences LLC [Abstract] | |||||||
| Estimated fair value of asset contributed to joint venture | $ 400,000 | ||||||
| X | ||||||||||
- Definition Capital contribution expense. No definition available.
|
| X | ||||||||||
- Definition The amount of non-cash charge in research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. No definition available.
|
| X | ||||||||||
- Definition Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) for proportionate share of equity method investee's income (loss). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Fair value portion of investments in an entity not consolidated. Includes, but is not limited to, investments in an entity that is affiliated with the reporting entity by means of direct or indirect ownership, an entity in which the reporting entity shares control of the entity with another party or group, an entity which the company has significant influence, but does not have control and subsidiaries that are not required to be consolidated and are accounted for using the equity or cost method. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The parent entity's interest in net assets of the subsidiary, expressed as a percentage. No definition available.
|
| X | ||||||||||
- Definition The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|